Back to top
more

Vertex Pharmaceuticals (VRTX)

(Real Time Quote from BATS)

$463.57 USD

463.57
357,922

+0.42 (0.09%)

Updated Sep 27, 2024 03:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.

Vertex Pharmaceuticals (VRTX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 15.61% and 4.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) second-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and pipeline progress.

CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.

    Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

    by Zacks Equity Research

    Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX

    by Zacks Equity Research

    The biotech sector was in focus last week on updates form Regeneron (REGN) and Bristol Myers (BMY).

    Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    Vertex Pharmaceuticals (VRTX) closed at $196.55 in the latest trading session, marking a -1.35% move from the prior day.

    Vertex (VRTX) Initiates Phase II Study on Pain Candidate

    by Zacks Equity Research

    Vertex (VRTX) starts phase II study for VX-548 to treat acute pain after bunionectomy surgery & expects to start another phase II study to treat acute pain after abdominoplasty surgery in a few weeks.

    VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    VRTX vs. PRTA: Which Stock Is the Better Value Option?

    If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now

    by Zacks Equity Research

    Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

    Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $197.89, moving -0.22% from the previous trading session.

    3 Reasons Growth Investors Will Love Vertex (VRTX)

    by Zacks Equity Research

    Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

    Alexion (ALXN) Hits Fresh High: Is There Still Room to Run?

    by Zacks Equity Research

    Alexion (ALXN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?

    by Zacks Equity Research

    AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    Vertex Pharmaceuticals (VRTX) closed at $200.54 in the latest trading session, marking a -0.83% move from the prior day.

    The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Intellia Therapeutics, Regeneron Pharmaceuticals, CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals

    3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data

    by Zacks Equity Research

    Intellia (NTLA) announces first-ever, promising clinical data on an in vivo CRISPR-based therapy. Stocks of CRSP, EDIT and BEAM rise on investor enthusiasm about their CRISPR-based candidates.

    Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $197.82, moving +1.79% from the previous trading session.

    David Borun headshot

    Stocks Roar Back on Infrastructure Expectations

    by David Borun

    The S&P 500 hits a fresh all-time high as Congress agrees to a bipartisan infrastructure bill.

    Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    Vertex Pharmaceuticals (VRTX) closed at $187.70 in the latest trading session, marking a -0.08% move from the prior day.

    Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

    by Zacks Equity Research

    The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

    CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases

    by Zacks Equity Research

    CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.

    Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $194.80, marking a +0.92% move from the previous day.

    CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data

    by Zacks Equity Research

    CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.